Cerity Partners LLC Buys 4,863 Shares of Gilead Sciences, Inc. $GILD

Cerity Partners LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 250,653 shares of the biopharmaceutical company’s stock after purchasing an additional 4,863 shares during the quarter. Cerity Partners LLC’s holdings in Gilead Sciences were worth $27,824,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rothschild Investment LLC grew its position in shares of Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the last quarter. Ignite Planners LLC boosted its stake in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 86 shares in the last quarter. Archer Investment Corp grew its holdings in Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the last quarter. Binnacle Investments Inc grew its holdings in Gilead Sciences by 14.3% in the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 88 shares during the last quarter. Finally, EPG Wealth Management LLC increased its position in shares of Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 89 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on GILD shares. UBS Group initiated coverage on Gilead Sciences in a report on Wednesday. They issued a “buy” rating and a $145.00 price target for the company. Citigroup raised their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday. Needham & Company LLC increased their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Daiwa Capital Markets raised their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Finally, The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.20.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 136,257 shares of company stock valued at $16,855,192. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Down 3.0%

GILD opened at $120.67 on Friday. The company has a fifty day moving average of $123.24 and a two-hundred day moving average of $117.41. The stock has a market capitalization of $149.71 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 0.66 and a beta of 0.33. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the company posted $2.02 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.